Search

everythinglearnresearchcommunity

for

Search:↓

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

Lowering HER2 levels with certain drugs may reduce metabolic syndrome risk in women.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Exosomes show promise for targeted treatment of HER2-positive breast cancer.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

Trastuzumab may cause tufted hair folliculitis as a side effect.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.

Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.

HER2-targeted or hormonal therapies improve quality of life for Sudanese breast cancer patients.

CDK4/6 inhibitors generally maintain quality of life in metastatic breast cancer patients, except for some side effects like diarrhea and hair loss.

Most patients treated with trastuzumab and paclitaxel experience some hair loss, but it's usually not severe.

Many young women with breast cancer experience poor quality of life, especially in sexual health and hair loss, but future outlook improves over time.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.

Localized breast cancer can affect skin and hair.

Treatment strategies for breast cancer affect blood health, causing issues like anemia and require nutritional counseling.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.